Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line ...
The American Journal of Managed Care1d
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
GlobalData on MSN2d
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...
emjreviews.com2d
Roche’s twice-yearly MS injection wins FDA approval
The FDA has approved Roche’s subcutaneous injection for relapsing multiple sclerosis (RMS) and primary progressive multiple ...
Managed Healthcare Executive2d
FDA Approves Subcutaneous Ocrevus for Multiple Sclerosis
Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive Multiple Sclerosis
Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...
Medscape5d
FDA Okays Subcutaneous Ocrelizumab for MS
Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.
BioSpace12d
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...
The American Journal of Managed Care15d
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in non-relapsing secondary progressive multiple sclerosis.
Pharmabiz2d
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...